Mechanism of action
Serostim® is an anabolic and anticatabolic agent that exerts its influence in in HIV‑associated wasting by interacting with specific receptors on a variety of cell types including myocytes, hepatocytes, adipocytes, lymphocytes, and hematopoietic cells. Some, but not all of its effects, are mediated by insulin-like growth factor-1 (IGF-1).
- Effects on protein, lipid, and carbohydrate metabolism: A 1-week study in 6 patients with HIV‑associated wasting has shown that treatment with Serostim® 0.1 mg/kg/day improved nitrogen balance, increased protein-sparing lipid oxidation, and had little effect on overall carbohydrate metabolism
- Effects on nitrogen and mineral retention: In the 1-week study in 6 patients with HIV‑associated wasting, treatment with Serostim® resulted in the retention of phosphorous, potassium, nitrogen, and sodium. The ratio of retained potassium and nitrogen during Serostim® therapy was consistent with retention of these elements in lean tissue
- Physical performance: Cycle ergometry work output and treadmill performance were examined in separate 12-week, placebo-controlled trials. In both studies, work output improved significantly in the group receiving Serostim® 0.1 mg/kg/day subcutaneously vs placebo. Isometric muscle performance, as measured by grip-strength dynamometry, declined, probably as a result of a transient increase in tissue turgor known to occur with Serostim® therapy